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Background: Retinoblastoma is a pediatric eye cancer associated with RB1 loss or MYCN ampliﬁcation (RB1+/
+MYCNA). There are controversies concerning the existence of molecular subtypes within RB1−/− retinoblasto-
ma. To test whether these molecular subtypes exist, we performed molecular proﬁling.
Methods: Genome-wide mRNA expression proﬁling was performed on 76 primary human retinoblastomas. Ex-
pression proﬁling was complemented by genome-wide DNA proﬁling and clinical, histopathological, and
ex vivo drug sensitivity data.
Findings: RNA and DNA proﬁling identiﬁed major variability between retinoblastomas. While gene expression
differences between RB1+/+MYCNA and RB1−/− tumors seemed more dichotomous, differences within the
RB1−/− tumorswere gradual. Tumorswith high expression of a photoreceptor gene signaturewere highly differ-
entiated, smaller in volume and diagnosed at younger age comparedwith tumorswith low photoreceptor signa-
ture expression. Tumors with lower photoreceptor expression showed increased expression of genes involved in
M-phase and mRNA and ribosome synthesis and increased frequencies of somatic copy number alterations.
Interpretation:Molecular, clinical and histopathological differences between RB1−/− tumors are best explained
by tumor progression, reﬂected by a gradual loss of differentiation and photoreceptor expression signature.
Since copy number alterations were more frequent in tumors with less photoreceptorness, genomic alterations
might be drivers of tumor progression.
Research in context: Retinoblastoma is an ocular childhood cancer commonly caused by mutations in the RB1
gene. In order to determine optimal treatment, tumor subtyping is considered critically important. However, ex-
cept for very rare retinoblastomas without an RB1mutation, there are controversies as to whether subtypes of
retinoblastoma do exist. Our study shows that retinoblastomas are highly diverse but rather than reﬂecting dis-
tinct tumor types with a different etiology, our data suggests that this diversity is a result of tumor progression
driven by cumulative genetic alterations. Therefore, retinoblastomas should not be categorized in distinct sub-
types, but be described according to their stage of progression.© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).aat 7, 1081 BT Amsterdam, The
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Retinoblastoma is a childhood cancer of the retina, usually caused by
bi-allelic inactivation of the RB1 tumor suppressor gene. In 40% of the
cases, patients have a hereditary predisposition due to the presence of
a germ line mutation in RB1. Only one somatic inactivation of RB1 is re-
quired in hereditary patients to develop retinoblastoma and therefore
they are often affected bilateral. While the non-hereditary form ofthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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leles, a subtype of retinoblastoma was recently described which lacks
mutations in RB1 but displays high level ampliﬁcation of the oncogene
MYCN (Rushlow et al., 2013). Besides the initiating hit (RB1 mutation
or MYCN ampliﬁcation), additional DNA mutations are likely required
for retinoblastoma to develop (Dimaras et al., 2008). Common chromo-
somal alterations observed in retinoblastomas are gains of chromosom-
al regions 1q, 2p and 6p, and losses at chromosome 16q (Thériault et al.,
2014).We and others have previously described differences in the level
of chromosomal instability between retinoblastomas, depending on age
of the patient, heritability and laterality (Herzog et al., 2001; Lillington
et al., 2003; Mol et al., 2014; Sampieri et al., 2009; van der Wal et al.,
2003; Zielinski et al., 2005).
In addition to copy number analyses, several gene expression studies
on retinoblastoma have been published (Chakraborty et al., 2007;
Ganguly and Shields, 2010; Kapatai et al., 2013; McEvoy et al., 2011).
It has been suggested that retinoblastomas have similar expression pro-
ﬁles and express genes involved in multiple differentiation programs
(McEvoy et al., 2011). However, in another recent study (Kapatai
et al., 2013), two different subtypes of retinoblastoma were identiﬁed
based on gene expression proﬁling. One group expressed genes associ-
ated with a range of different retinal cell types, suggesting a progenitor
cell of origin, while the second group showed high expression of cone
photoreceptor associated genes, suggesting derivation from a cone
photoreceptor cell precursor. So, while it is well-established that there
are 2 genomic subtypes (RB1−/− and RB1+/+MYCNA) there is controver-
sy surrounding gene expression subtypes, in particular within the
RB1−/− tumor subtype.
To address this issue, we have performed transcriptome-wide ex-
pression proﬁling of a large, diverse and randomly selected set of retino-
blastomas. Subsequently, expression proﬁles were associated with copy
number proﬁles, clinical characteristics and ex vivo drug sensitivity data.
2. Material and Methods
2.1. Patient Samples
Retinoblastoma samples from a consecutive patient series were col-
lected after primary enucleation (without receiving previous treatment)
at the VU University Medical Center (Amsterdam, The Netherlands),
which is the national retinoblastoma referral center in the Netherlands.
Incisions were made in the enucleated eyes and tumor samples were
taken and immediately snap frozen in liquid nitrogen and stored at
−80 °C. In some cases, an additional tumor sample was used for cultur-
ing, as described previously (Schouten-vanMeeteren et al., 2001). Histo-
pathology was determined at initial pathological diagnosis by a
retinoblastoma-experienced pathologist and independently by an oph-
thalmologist and pediatric oncologist. Tumor location was determined
on funduscopy results and/or fundus photos by an ophthalmologist.
The diseasewas staged according to the twomost common classiﬁcation
systems for retinoblastoma, the Reese–Ellsworth Classiﬁcation (Reese
and Ellsworth, 1963) and the International Intra-ocular Retinoblastoma
Classiﬁcation (ABC-classiﬁcation) (Linn Murphree, 2005). This prospec-
tive study was conducted in accordance with recommendations of the
local ethics committee, with waiver of informed consent (IRB00002991
reference 2014.360).
2.2. DNA Extraction and Copy Number Proﬁling
Genomic DNA from frozen tumor retinoblastoma specimens was iso-
latedwith theNucleoSpin Tissue kit (Macherey-Nagel, Düren, Germany).
DNA quality was analyzed for high molecular bands N20 kb by agarose
gel electrophoresis. DNA concentration and OD 260/280 ratio were de-
termined with the Nanodrop ND-1000 spectrophotometer (NanoDrop
Technologies, Wilmington, USA). DNA yields and quality were within
the same range for all samples. Microarray-based DNA genotypingexperiments were performed at ServiceXS (ServiceXS B.V., Leiden, The
Netherlands) using the HumanOmni1-Quad BeadChip (Illumina Inc.,
San Diego, U.S.A.), as described previously (Mol et al., 2014).
2.3. RNA Extraction and Expression Proﬁling
Frozen tumor samples were homogenized in a TRIzol reagent
(Invitrogen, Carlsbad, California, U.S.A.) with a rotor–stator homogeniz-
er, and RNA was extracted following the manufacturer's instructions.
TRIzol extracted RNA was treated with rDNase (Macherey-Nagel,
Düren, Germany) to digest any contaminating DNA and subsequently
puriﬁed with the NucleoSpin RNA Clean-up XS kit (Macherey-Nagel).
Three samples (VUMC-Rb-76, VUMC-Rb-81, and VUMC-Rb-82) were
extracted with the AllPrep RNA/DNA/Protein Mini Kit (Qiagen, Venlo,
The Netherlands), following the manufacturer's instructions. Quality
control, RNA labeling, hybridization anddata extractionwere performed
at ServiceXS B.V. RNA concentration was measured using the Nanodrop
ND-1000 spectrophotometer (Nanodrop Technologies). The RNA quali-
ty and integrity were determined using Lab-on-chip analysis on the
Agilent 2100 Bioanalyzer (Agilent Technologies, Inc., Santa Clara, CA,
U.S.A.) and on the Shimadzu MultiNA RNA analysis chips (Shimadzu
Corporation, Kyoto, Japan). Only RNA samples that passed the quality
criteria of an OD 260/280 ratio of ≥1.8 and an RNA Integrity number
(RIN) of ≥7 were processed for expression proﬁling. Biotinylated cRNA
was prepared using the Affymetrix 3′ IVT Express Kit (Affymetrix,
Santa Clara, CA, USA) according to the manufacturer's speciﬁcations
with an input of 100 ng of total RNA. The quality of the cRNA was
assessed using the Shimadzu MultiNA in order to conﬁrm if the average
fragment size was according to requirements of Affymetrix. Per sample,
7.5 μg cRNA of the obtained biotinylated cRNA samples was fragmented
and hybridized in a ﬁnal concentration of 0.0375 μg/μL on the Affymetrix
[HT HG U133 + PM96] (Affymetrix, Santa Clara, California, U.S.A.). After
an automated process of washing and staining by the GeneTitanmachine
(Affymetrix) using the Affymetrix HWS Kit for GeneTitan (part nr.
901530), absolute values of expressionwere calculated from the scanned
array using the Affymetrix Command Console v3.2 software. Micro-array
data is available at Gene expression omnibus (GSE59983).
2.4. Micro-array Data Analysis
Absolute expression values were normalized with robust multichip
array (RMA) normalization implemented by affy Bioconductor
(Gautier et al., 2004) package and log2-transformed. For each ofﬁcial
HGNC symbol targeted by multiple probes, only the probe closest to
the 3′-prime end was used for further analysis. Agglomerative hierar-
chical (Ward, complete-linkage, average-linkage andMcQuitty) cluster-
ing was performed on pairwise inverse absolute Pearson correlations.
Differential expression testing was performed by generalized linear
modeling of indicated (co-)variates on normalized log2-transformed
expression values implemented by limma Bioconductor package
(Smith, 2005). Obtained p-values were corrected for multiple hypothe-
sis testing by Benjamini & Hochberg false discovery rate (FDR) adjust-
ments (Benjamini et al., 1995). Obtained FDR-adjusted two-sided p-
values b 0.05 were considered signiﬁcant.
Copy number estimates and allelic intensity ratios exported by
Illumina Beadstudio were normalized with tQN-procedure (Staaf et al.,
2008). Subsequently, log2-R-ratios (LRR) were calculated from normal-
ized copy number estimates of the tumors and matched blood samples.
For tumors with no matching blood sample, sex-matched pooled base-
lines from all blood samples were used to calculate log2-R ratios.
CGHcall (van de Wiel et al., 2007) and CGHregions (Van de Wiel and
Van Wieringen, 2007) implementing the DNAcopy segmentation algo-
rithm were used to create a reduced segment matrix containing ﬁve
copy number levels. All parameters used for copy number segmenta-
tions (performed by “segmentData” function) used were defaults ex-
cept the deﬁnition of small segments (clen = 25) and the amount of
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For association of total copy number changes with photoreceptorness,
the number of affected base pairs (in Mbps) between the groups was
analyzed with the Wilcoxon rank sum test. The association between
copy number levels and expression estimates was quantiﬁed by ﬁtting
a linear model between continuous copy number estimates (segment
means) and log2-transformed normalized expression estimates and
testing the slopes for signiﬁcance. Resulting p-values were corrected
formultiple hypothesis testing by Benjamini &Hochberg false discovery
rate (FDR) adjustments where two-sided p-values b 0.05 were consid-
ered signiﬁcant.
2.5. Drug Sensitivity Assays
Ex vivo drug sensitivity assays were performed on primary retino-
blastoma samples using the colorimetric 3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyltetrazolium bromide (MTT) cell viability assay (van
Meerloo et al., 2011). Some of the drug sensitivity data were described
previously (Schouten-van Meeteren et al., 2001). Cells were exposed
to the drugs in duplicate in six serial dilution steps for 96 h at 37 °C.
The following drugs and concentration ranges were used: actinomycin
D (0.000015–1.5 μg/mL), cytarabin (0.007812–256 μg/mL), carboplatin
(0.49–500 μg/mL), cisplatin (0.0488–50 μg/mL), doxorubicin (0.03125–
32 μg/mL), idarubicin (0.00781–8 μg/mL), 4-hydroperoxy-ifosfamide
(0.098–100 μg/mL), thiotepa (0.032–100 μg/mL), vincristine (0.064–
400 mg/mL), etoposide (0.08–200 μg/mL), 6-thioguanine (0.098–
100 μg/mL), and cladribine (0.002–200 μg/mL) as described previously
(Schouten-van Meeteren et al., 2001). A minimum of 1 drug was tested
for 1 tumor sample and a maximum of 12 drugs tested for 10 tumor
samples (median = 11 drugs tested per tumor sample). Resulting
IC50 valueswere calculated based on triplicates andwere calculated rel-
ative to untreated controls with drug-free medium.
2.6. Internal Validation of Microarray Gene Expression by qPCR
For a selected set of genes, qPCR validation of microarray gene ex-
pression results was done by “best-coverage” Taqman gene expression
assays (Life Technologies Europe BV, Bleiswijk, The Netherlands). By
means of duplex PCR reactions using GAPDH as internal control, relative
gene expression of selected genes was determined. Normalized ratios
between genes of interest andGAPDHwere calculated by the Lightcycler
480 relative gene expression quantiﬁcation module. Log2-transformed
normalized ratios were compared with log2-transformed micro-array
expression estimates.
2.7. Statistics
Base functionality of R (version 3.1.2 “Pumpkin Helmet”) was used
for hypothesis testing. The Wilcoxon rank sum test was used for com-
paringmeans of continuous variables between two independent groups
andWilcoxon signed rank sum test for two dependent groups. Kruskal–
Wallis rank sum test was used for variables with 3 ormore independent
groups. For comparing means between ordinal variables, linear-by-
linear association testing was performed implemented by the “coin”
R-library. The exact binomial test was used as a sign test on a set of lin-
ear regression slopes. Two-sided p-values b 0.05 were considered
signiﬁcant.
3. Results
3.1. Unsupervised Analysis of Retinoblastoma mRNA Expression Proﬁles
In order to identify possible differences in gene expression proﬁles of
retinoblastomas, standardized log2-transformed expression estimates
were used as input for unsupervised hierarchical clustering (UHC) of
76 retinoblastoma samples. Ward's and average-linkage agglomerativeclustering of inverse absolute Pearson correlations between samples is
summarized in a dendrogram (Fig. 1A). The Ward's dendrogram was
pruned at an arbitrary k = 3, forcing the cohort to be categorized in
three clusters: Ward's retinoblastoma cluster 1 (N = 26, red color),
Ward's retinoblastoma cluster 2 (N= 46, green color), and Ward's ret-
inoblastoma cluster 3 (N = 4, blue color) with dissimilarity heights of
0.18, 0.17, and 0.12, respectively. To test the robustness of the three
Ward's clusters, clustering with McQuitty and complete-linkage was
also performed, (Fig. S1). Leafs (representing samples) of resulting den-
drogramswere colored based on the initial threeWard's retinoblastoma
clusters. The hierarchical agglomeration of the retinoblastoma samples
into clusters differed between clustering algorithms. Whereas Ward's
retinoblastoma cluster 3 (blue labels) was consistently clustered as a
separate branch, Ward's retinoblastoma clusters 1 (red) and 2 (green)
were agglomerated together in average-linkage, complete-linkage and
McQuitty. Remarkably, average-linkage clustering placed Ward's reti-
noblastoma clusters 1 and 2 in a single branch where the similarities
of samples in clusters 1 and 2 gradually decreased. All these observa-
tions were in agreement with principal component analysis (PCA,
Fig. 1B), which shows that the three-dimensional distance between
Ward's retinoblastoma cluster 3 and Ward's retinoblastoma clusters 1
and 2 combined was larger than the distance between Ward's retino-
blastoma clusters 1 and 2. Taken togetherWard's retinoblastoma cluster
3 appeared distinct from retinoblastoma groups 1 and 2, while the dif-
ferences between Ward's clusters 1 and 2 could be more continuous
rather than dichotomous.
In a recent gene expression proﬁling study (N = 21), three retino-
blastoma groups were identiﬁed (Kapatai et al., 2013). Based on a de-
tailed inspection of retina marker expression, one of the three groups
was considered to largely represent normal retinal tissue. To assess
the similarity of our Ward's clusters with Kapatai's subgroups, expres-
sion box plots of 5 cell cycle markers (E2F1, E2F2, E2F3, PCNA, CCNE1),
5 rod photoreceptor markers (RHO, CNGB1, ROM1, PDE6G, CNGA1) and
5 cone photoreceptor markers (PDE6C, PDE6H, GNAT2, OPN1SW, ARR3)
weremade (Fig. 1C) (Sharon et al., 2002). For CCNE1 (cell cyclemarker),
CNGB1 (rod photoreceptor marker) and ARR3 (cone photoreceptor
marker) validation of the micro-array gene data was performed by
qPCR-assays (Fig. 1D). Gene expression values measured by qPCR
were highly similar to the micro-array data and resulted in similar dif-
ferences between Ward's retinoblastoma clusters (Fig. S2). The level
of expression of the selected markers differed signiﬁcantly between
the Ward's expression groups (see Table S1 for a detailed list of fold
changes and p-values). Ward's retinoblastoma clusters 1 and 2 were
characterized by relatively high expression of cell cycle markers and
low expression of rod photoreceptor markers relative to Ward's retino-
blastoma cluster 3. High expression of both cone and rod photoreceptor
markers and low expression of cell cycle markers was speciﬁc for
Ward's retinoblastoma cluster 3 suggesting contamination with normal
retinal tissue. Therefore this small group was omitted in subsequent
analyses analogous to the study from Kapatai et al. (2013).
Expression of cone photoreceptormarkers was higher inWard's ret-
inoblastoma cluster 2 compared with cluster 1. However, the difference
was gradual and not dichotomous, exempliﬁed by expression of ARR3 in
micro-array and qPCR validation (Fig. 1D). Gradual expression differ-
ences also hold for the two other tested markers, CCNE1 (cell cycle)
and CNGB1 (rod). This supports again that Ward's retinoblastoma clus-
ters 1 and 2 do not appear to be distinct entities. Although the RB1+/
+MYCNA tumors were not clustered as separate branches in the unsu-
pervised (all genes) Ward's clustering (Fig. 1A), for selected markers
they presented as outliers (Figs. 1C and S2). To test whether there
were more genes that had a similar more dichotomous difference in
gene expression such as CCNE1, differential gene expression analysis
was performed between RB1+/+MYCNA (N = 2) and all other tumors
in Ward's retinoblastoma clusters 1 and 2 (N = 70). In total, 1800
genes were signiﬁcantly differentially expressed (see Table S2). Some
of themost signiﬁcantly differential genes (top 50 of Table S2) included
Fig. 1. Transcriptome-wide unsupervised hierarchical clustering stratiﬁes the cohort in 3Ward's retinoblastoma clusters. (A) Dendrogram of transcriptome-wide unsupervised hierarchi-
cal clustering of all primary retinoblastoma samples (N= 76) byWard and average-linkage algorithms. TheWard's dendrogram is pruned at an arbitrary k= 3 yielding three retinoblas-
toma clusters: cluster 1 in red, cluster 2 in green and cluster 3 in blue. (B) Principal component analysis visualized in a 3-dimensional scatter plot, in which the axes represent the ﬁrst 3
principal components. Colors refer to the identiﬁed retinoblastoma clusters and the data demonstrate concordance betweenUHC and PCA clusters. (C) Expression box plots of 5 cell cycle
markers (E2F1, E2F2, E2F3, CCNE1, PCNA; top panel), 5 rod photoreceptor markers (RHO, CNGB1, ROM1, PDE6G, CNGA1; middle panel), and 5 cone photoreceptor markers (PDE6C, PDE6H,
GNAT2,OPN1SW,ARR3; bottompanel). Cluster 1 is indicated in red, cluster 2 in green, and cluster 3 in blue. TheRB1+/+MYCNA tumors are indicated by arrowsor asterisks. (D) Validation of
gene expression differences by Taqman relative quantiﬁcation (qPCR) of gene expression (GAPDH as internal control). X-axis shows log2-transformed Taqman relative gene expression of
CCNE1, CNGB1 and ARR3 and Y-axis log2-transformed micro-array gene expression estimates.
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MCM6, WEE1 and RBL1. For these genes, the dichotomous differences
in gene expression are visualized (Fig. S3).
3.2. Retinoblastomas have Gradually Differing Gene Expression Signatures
To further test the graduality of expression differences between
Ward's retinoblastoma clusters 1 and 2, we performed a genome-wide
differential gene expression analysis. In total, 6324 out of 19,488
(32.5%) genes were found to be differentially expressed (FDR-adjusted
p-values b 0.05) between the twoWard's clusters (Table S3). All differ-
entially expressed genes were used for the hierarchical clustering
(Fig. 2). Ward's retinoblastoma cluster 1 was characterized by high ex-
pression of genes present in gene cluster 1 (N=2999, purple branches)
whereas Ward's retinoblastoma cluster 2 showed high expression of
genes in gene cluster 3 (N = 2753, orange branches). Expression of
genes in gene cluster 2 (N = 572, black branches) was on average
higher inWard's retinoblastoma cluster 2 relative to cluster 1, although
they are not consistent for all samples. Gene ontology analysis of the
three gene clusters was performed using DAVID functional annotationclustering. Functional annotation classes with enrichment scores
above 5 are summarized in Table 1 (full DAVID reports in Table S4).
High expression of genes involved in M-phase and in mRNA and ribo-
some synthesis characterized Ward's retinoblastoma cluster 1, while
genes highly expressed in Ward's retinoblastoma cluster 2 were in-
volved in photoreceptor functions, including visual perception of light
and photo-transduction. Additionally, genes involved in inﬂammation,
woundhealing and antigen presentation (gene cluster 2, black branches
Fig. 2 and Table 1) were on average higher in Ward's retinoblastoma
cluster 2.
Based on the heatmap colors (Fig. 2) it can be hypothesized that the
gene expression differences between Ward's retinoblastoma clusters 1
and 2 were continuous rather than dichotomous. To further test this,
themean expression of gene cluster 1 (“M-phase, mRNA/ribosome syn-
thesis signature”) and gene cluster 3 (“photoreceptor signature”) was
calculated for each sample. Themean expression of both differential sig-
natures is displayed along with color-coded sample information, with
samples ordered by decreasing photoreceptor signature expression
(Fig. 3). The data conﬁrmed that variability in photoreceptor signature
was continuous and not dichotomous. Although this gradual change
age at diagnosis
tumor volume
laterality
heredity
tumor location
UHC group
Fig. 2. Hierarchical clustering of differentially expressed genes between Ward's retinoblastoma clusters 1 and 2 reveals distinct gene clusters. Hierarchical clustering of signiﬁcantly dif-
ferentially expressed genes (N = 6324) between retinoblastoma clusters 1 and 2. Sample properties are indicated at the top with colored bars; retinoblastoma clusters: cluster 1 in
red, cluster 2 in green; tumor location: peripheral in red, central in green, full-blown in gray with a cross; heredity: non-hereditary retinoblastoma in red, hereditary in green; laterality:
unilateral in red, bilateral in green; tumor volume: continuous scale from red (large) to green (small), not available in gray; age at diagnosis: continuous scale from red (older) to green
(young). The heatmap represents standardized expression estimatesmapped to a continuous green-to-red color scalewhere greenmeans low expression and redmeans high expression.
Three gene clusters are colored in purple (cluster 1), black (cluster 2), and orange (cluster 3). The RB1+/+MYCNA tumors are indicated by red labels.
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the clustering was useful to detect genes that were differentially
expressed across retinoblastoma samples. The gradual decrease of the
photoreceptor signature was accompanied by a gradual increase of the
M-phase and mRNA/ribosome synthesis expression signature (p-
value b 2.2E−16, R2 = 0.90). The immune signature was less strongly
associated with the photoreceptor (p-value = 9.28E−7, R2 = 0.29)
and M-phase (p-value = 1.77E−7, R2 = 0.32) signatures as shown in
Fig. S4. Three tumors (VUMC-Rb-02, VUMC-Rb-17 and VUMC-Rb-99)
from Ward's Rb cluster 2, clustered together with Ward's Rb cluster 1
in supervised analysis (Fig. 2). In agreement, these three tumors had an
intermediate photoreceptorness andM-phase andmRNA/ribosome syn-
thesis expression, which complicated the initial dichotomous stratiﬁca-
tion. The two RB1+/+MYCNA tumors without RB1 mutation but with
focalMYCN ampliﬁcations (Rushlow et al., 2013), showed low photore-
ceptor expression and high M-phase and mRNA/ribosome synthesis ex-
pression compared with the median of the cohort. Furthermore, theWard's retinoblastoma cluster 1 tumors showed a higher expression
of MYCN compared with Ward's retinoblastoma cluster 2 tumors
(log2(fold change) = 0.55, p-value = 4.7E−3). For further analysis,
the mean photoreceptor signature expression was taken as a measure
of photoreceptornesswhichwas used to further characterize the retino-
blastoma cohort. Important to note is that photoreceptorness was
quantiﬁed by the mean expression of gene cluster 3 (2753 genes, or-
ange branches Fig. 2, Table S3). Although this gene set is highly enriched
for photoreceptor ontologies (Table S4), not every single gene in this
gene set is annotated with photoreceptor-related ontologies.
3.3. Loss of Photoreceptorness is Associated with Increased Somatic Copy
Number Alteration Frequencies
To investigate whether photoreceptorness was associated with so-
matic copy number alterations (SCNA), whole genome copy number
(CN) proﬁling was performed when tumor DNA was available. For 43/
Table 1
Gene ontology analysis of differentially expressed genes between Ward's retinoblastoma clusters 1 and 2.
Gene
cluster
DAVID annotation cluster summary Enrichment
score
High in Ward's
retinoblastoma
cluster
1 (purple) Mitotic cell cycle, M phase, mitosis, cell division, nuclear division 11.61 1
1 (purple) Transcription, regulation of transcription, regulation of RNA metabolic process 10.05 1
1 (purple) RNA processing/splicing, mRNA metabolic process, nuclear mRNA splicing 6.32 1
1 (purple) Ribonucleoprotein complex biogenesis, ribosome biogenesis, rRNA/ncRNA/ processing/metabolic process 5.74 1
2 (black) Response to wounding, defense response, inﬂammatory response 19.45 2
2 (black) Antigen processing and presentation 8.07 2
2 (black) Positive regulation of immune system response, acute/humoral/innate inﬂammatory process, complement
activation
6.98 2
2 (black) Cell motion/migration/motility 5.53 2
2 (black) Vasculature development, angiogenesis 5.28 2
2 (black) Wound healing, hemostasis, blood coagulation 5.14 2
3 (orange) Visual perception, sensory perception (of light stimulus), neurological system process, cognition 9.28 2
3 (orange) Phosphate metabolism, phosphorylation, protein amino acid phosphorylation 5.08 2
3 (orange) Detection of light/external/abiotic stimulus, photo-transduction, detection of visible light 5.05 2
Fig. 3. Quantiﬁcation of differential signatures in relation to clinical and histopathological variables. Gene expression differences betweenWard's retinoblastoma cluster 1 (red symbols)
andWard's retinoblastoma cluster 2 (green symbols) appears continuous, not dichotomous. Gene expression of the photoreceptor signature is given by crosses; triangles indicate theM-
phase and mRNA/ribosome synthesis signature. Tumors are sorted by photoreceptor signature gene expression. Corresponding clinical and histopathological determinations are given in
aligned color-coded boxes including a legend with color-value mappings. Results of statistical analyses are provided in Table 2. The RB1+/+MYCNA tumors are indicated by red labels.
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SCNA proﬁles were available. To visualize the difference in SCNA be-
tween tumors with different photoreceptorness, the 43 tumors were
categorized into quartiles based on photoreceptorness (Q1=25% of tu-
mors with highest photoreceptorness, Q4= 25% of tumors with lowest
photoreceptorness). It is shown that themean photoreceptorness (one-
way ANOVA p-value b 2.2E−16) and mean overall genomic instability
(one-way ANOVA p-value= 4.61E−05) differed signiﬁcantly between
the photoreceptorness quartile groups (Fig. 4). Karyogram overviews of
SCNA frequencies stratiﬁed by photoreceptorness quartiles clearly show
that tumors with lower photoreceptorness have higher frequencies of
SCNA (Fig. 5A).
For each approved HGNC gene symbol that was probed by both
RNA and DNA arrays, it was tested whether SCNA were associated
with photoreceptorness by linear regression slope testing of
photoreceptorness on copy number estimates (Fig. 5C). For 4146
genes, copy number estimates were signiﬁcantly associated with
photoreceptorness, indicated by the red dots (Fig. 5C). The relation
between copy numbers and photoreceptorness was positive for 1889/
4146 (45.6%) genes and negative for 2257/4146 (54.4%) genes. To test
for which genes copy numbers had an effect on gene expression (gene
dosage effect), linear regression slope testing of copy number estimates
on expression estimates was performed (Fig. 5B). In total, 1773 genes
showed a signiﬁcant gene dosage effect and for 1727/1773 (97.4%, indi-
cated by red dots in Fig. 5B) the gene dosage effect was in the expected
direction (positive linear regression slope: more copies correlated with
more expression and less copies correlated with less expression). The
strongest gene dosage effects were observed at the 2p24.3 region har-
boring theMYCN gene and at 13q14where RB1 is located. Furthermore,
strong gene dosage effectswere identiﬁed at 6p and 16q. In Supplemen-
tary Table S5 a complete list of the results is given.3.4. The Degree of Photoreceptorness is Associated with Clinical and Histo-
pathological Features
Visual inspection of photoreceptorness and several clinical and his-
topathological variables (Fig. 3) called for further investigation of
photoreceptorness in relation to tumor characteristics. To determine
the statistical signiﬁcance of the relations between photoreceptorness
and clinical and histopathological determinations, hypothesis testingFig. 4. Loss of photoreceptorness is strongly associated with increased frequencies of
SCNA. Photoreceptorness was used to stratify the cohort in quartiles (Q1: 25% of tumors
with the highest photoreceptorness, Q4: 25% of tumors with the lowest
photoreceptorness). For each quartile, boxplots are shown for photoreceptorness (left)
and genomic instability (right). Photoreceptorness was statistically different between
the photoreceptorness quartiles (one-way ANOVA, two-tailed p-value b 2.2E–16). Total
genomic instability, in our study deﬁned as the number of megabases of the genome al-
tered by SCNA, was inversely correlated with the photoreceptorness quartiles (one-way
ANOVA, two-tailed p-value b 4.61E–05).was performed (Table 2). For numeric independent variables (age at di-
agnosis and tumor volume), Table 2 describes the mean and standard
error of the mean for each photoreceptorness quartile. Quartile stratiﬁ-
cationwas performed for illustrative purposes andwas not required nor
used for Wilcoxon signed rank test. Patients with tumors that showed
high photoreceptorness were diagnosed at signiﬁcantly younger age
(p-value = 1.26E−11) and had signiﬁcantly larger tumors (p-
value = 3.53E−12) than patients with low photoreceptorness.
For other characteristics, the level of photoreceptorness was calcu-
lated (Table 2). In agreement with young age, tumors from bilateral pa-
tients showed higher photoreceptorness than tumors from unilateral
patients (p-value = 4.01E−03). There was no signiﬁcant difference in
photoreceptorness between hereditary and non-hereditary patients
(p-value = 0.06). Photoreceptorness was positively associated with
the degree of differentiation, as to be expected. Consistently, rosettes
(in particular Flexner–Wintersteiner rosettes)which are a characteristic
of photoreceptor differentiation (Dickson et al., 1976; Gonzalez-
Fernandez et al., 1992), were more often seen in tumors with high
photoreceptorness than in tumors with low photoreceptorness
(rosettes p = 4.50E−03, Flexner–Wintersteiner rosettes p = 2.18E−
03). Tumors located in the central part of the retina (close to the macu-
la) had higher photoreceptorness than tumors located in the periphery
(p = 0.02).
We could not detect a signiﬁcant association between the histopath-
ological risk factor optic nerve/choroid invasion and photoreceptorness,
possibly due to low numbers of invasion in our cohort, with only 9/76
(12%) of tumors showing post-laminar optic nerve invasion and 1/76
(2%) showing extensive choroid invasion. Also, different stages of dis-
ease, as deﬁned by the International intra-ocular retinoblastoma ABC-
classiﬁcation and the Reese Ellsworth classiﬁcation did not correspond
to a speciﬁc gene expression proﬁle.
Tested variables are sorted by statistical signiﬁcance. FW =
Flexner−Wintersteinter, RE = Reese−Elsworth, WSRT = Wilcoxon
signed rank test, WRST—Wilcoxon rank sum test, LBL = linear-by-line-
ar, KWRST = Kruskal–Wallis rank sum test, SEM = standard error of
the mean. * indicates signiﬁcant (p-value b 0.05).
3.5. Loss of Photoreceptorness is Related to Drug Sensitivity ex vivo, in Par-
ticular Actinomycin D
To determine whether photoreceptorness was associated with drug
sensitivity, we used data from a study in which the ex vivo drug sensi-
tivities of retinoblastoma specimens from our cohort were determined
(Schouten-van Meeteren et al., 2001). These data were complemented
by drug sensitivity data that were not reported before. Data were
available for 30/72 (41.7%) retinoblastoma samples. MTT assays
were performed using fresh tumor material from enucleated eyes
and median lethal concentrations (LC50 values) were determined
from dose–response curves of twelve chemotherapeutic drugs
based on triplicates relative to untreated controls. The number of ret-
inoblastoma samples for which an LC50 value could be determined dif-
fered between the 12 tested drugs due to sample availability and ranged
from N = 12 for 6-thioguanine to N = 29 for carboplatin, cisplatin,
cytarabine, doxorubicin, ifosfamide and vincristine. Linear regression
of photoreceptorness was performed on log10-transformed LC50-
values (Fig. 6). To test whether tumors with low photoreceptorness in
general were more chemosensitive, the slopes of the association
between photoreceptorness and log-transformed LC50 values were
calculated. For 10/12 (83.3%) drugs, the slope was positive. In case
photoreceptorness would have been unrelated to chemosensitivity in
general, one would expect that the slopes have had a similar chance
to be positive as well as negative. To test this, the exact binomial test
(also known as sign-test) was used. This test indicated that it is unlikely
(p-value = 0.02) that the degree of photoreceptorness is not related to
chemosensitivity. The log-transformed LC50s of thiotepa (slope= 0.63,
p-value = 7.92E−04), actinomycin D (slope = 2.23, p-value =
Fig. 5.Karyogramoverviewof SCNA and its relation to photoreceptorness and gene expression. (A) For each photoreceptorness quartile, SCNA frequencies (gains in red, losses in blue) are
visualized for all chromosomes except the Y-chromosome. (B–C) For each approved HGNC symbol that was probed by both RNA and DNAmicroarrays, the association between (B) copy
number estimates and gene expression and (C) copy numbers and photoreceptorness is visualized. Negative log10-transformed p-values of linear regression slope tests are plotted along
genomic coordinates. Red dots indicate signiﬁcant p-values (p-value = 0.05 gives−log10(0.05) = 1.3).
667I.E. Kooi et al. / EBioMedicine 2 (2015) 660–6708.28E−03), doxorubicin (slope = 0.64, p-value = 0.026) and
carboplatin (slope= 0.41, p = 0.034) showed a signiﬁcant linear asso-
ciation with photoreceptorness. In the case of actinomycin D the slope
of the linear association was steepest and therefore indicative of the
most pronounced effect: a reduction of themeanphotoreceptor expres-
sion signature by one unit increased the potency of actinomycin Dmore
than 100-fold (10 ^ 2.23 = 169).
3.6. Validation of Differential Expression Signatures by an Independent
Expression Proﬁling Dataset
To validate the expression differences between retinoblastoma
samples in our cohort, we compared our results with an indepen-
dent publicly available primary retinoblastoma gene expression
dataset (Gene expression omnibus, GSE29686, N = 55) (McEvoy
et al., 2011). Unsupervised hierarchical clustering subdivided the
McEvoy cohort into 4 separate Ward's retinoblastoma clusters
(Fig. S5A). Detailed inspection of cell cycle markers, rod and cone
photoreceptor markers and immune cell markers suggested that
Ward's retinoblastoma cluster 3 could reﬂect samples that contained a
large proportion of normal-retina cells (Fig. S5D).Ward's retinoblastoma
cluster 4 displayed high expression of immune cell markers, indicative of
contamination with blood cells or tumor inﬁltrating lymphocytes.
Ward's retinoblastoma clusters 1 and 2 both displayed high expressionof cell cycle makers, but only Ward's retinoblastoma cluster 2 showed
high gene expression of cone photoreceptor markers (Fig. S5D). There-
fore, Ward's retinoblastoma cluster 3 (alleged normal-retina samples)
and Ward's retinoblastoma cluster 4 (immune/blood cell inﬁltrates)
were excluded from further analysis and differential expression analysis
was restricted to the remaining Ward's retinoblastoma clusters 1 and 2.
Strikingly, 2887 genes were differentially expressed between groups 1
and 2 (Fig. S6 and Table S6). Gene ontology enrichment analysis of the
identiﬁed differentially expressed genes yielded results (Table S7) very
comparable with our Ward's retinoblastoma cluster 1 versus cluster 2
comparison (Table S4). Similar to our data, a gradual loss of a gene ex-
pression signature highly enriched for photoreceptor ontologies
(Fig. S5, top branch of the gene dendrogram) correlated with gradual in-
crease of genes related to M-phase, mRNA and ribosome synthesis
(Fig. S5, bottom branch of the gene dendrograms). Furthermore,
genome-wide fold-changes of the McEvoy cohort were compared with
fold-changes of our cohort (Fig. S7). In total, 18,465/19,488 (94.8%)
genes could be matched and showed a strong positive correlation
(Pearson correlation = 0.77, linear regression slope = 0.69, p-
value b 2.2E−16) demonstrating the high concordance between
both datasets. These results show that in both datasets the retino-
blastoma tumor cohort was not homogeneous with respect to
gene expression and that similar expression differences were iden-
tiﬁed in independent datasets.
Table 2
Hypothesis testing of photoreceptorness and clinical and histopathological variables.
Independent variable Descriptive statistics
mean ± SEM
Hypothesis
testing p-value
(statistical test)
Volume measured by MRI (mm3) 3.53E−12*
(WSRT)Q1 1016.6 ± 109.8
Q2 1147.0 ± 80.4
Q3 1182.2 ± 160.8
Q4 2056.4 ± 326.7
Age at diagnosis (months) 1.26E−11*
(WSRT)Q1 10.4 ± 1.2
Q2 10.8 ± 1.2
Q3 25.2 ± 5.3
Q4 35.1 ± 4.2
Differentiation Photoreceptorness 1.96E−03*
(LBL)Poor 6.0 ± 0.06
Moderate 6.2 ± 0.08
Well 6.3 ± 0.03
Flexner–Wintersteiner rosettes Photoreceptorness 2.18E−03*
(WSRT)Absent 5.9 ± 0.07
Present 6.2 ± 0.04
Laterality Photoreceptorness 4.01E−03*
(WSRT)Unilateral 6.1 ± 0.04
Bilateral 6.3 ± 0.04
Rosettes Photoreceptorness 4.50E−03*
(WSRT)Absent 5.9 ± 0.08
Present 6.1 ± 0.04
Tumor location Photoreceptorness 0.02* (WSRT)
Central 6.2 ± 0.06
Periphery 6.0 ± 0.09
Could not determine (full blown) 6.1 ± 0.04
Heredity Photoreceptorness 0.06 (WSRT)
Non-hereditary 6.1 ± 0.05
Hereditary 6.2 ± 0.04
Uni/multifocal Photoreceptorness 0.10 (WSRT)
Unifocal 6.2 ± 0.06
Multifocal 6.0 ± 0.05
RE-classiﬁcation Photoreceptorness 0.21 (LBL)
III 6.3 ± 0.06
IV 6.4 (only 1 tumor)
V 6.1 ± 0.04
Optic nerve invasion Photoreceptorness 0.48 (LBL)
None 6.2 ± 0.05
Pre-laminar 6.2 ± 0.07
Intra-laminar 6.1 ± 0.09
Post-lamina 6.1 ± 0.12
ABC-classiﬁcation Photoreceptorness 0.57 (LBL)
B 6.0 ± 0.15
C 6.3 ± 0.07
D 6.1 ± 0.06
E 6.2 ± 0.05
Choroid invasion Photoreceptorness 0.70 (LBL)
None 6.1 ± 0.04
Focal 6.1 ± 0.11
Extensive 6.3 (only 1 tumor)
Gender Photoreceptorness 0.71 (WSRT)
Female 6.1 ± 0.05
Male 6.1 ± 0.05
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Our study showed that expression of a photoreceptor gene signature
was associated with differentiation and inversely correlated with anM-
phase and mRNA/ribosome synthesis gene signature, tumor volume
and age at diagnosis. The continuous rather than dichotomous loss of
photoreceptorness in our retinoblastoma cohort may have been caused
by a gradual dedifferentiation of all tumor cells simultaneously or by the
emergence of dedifferentiated subclones that could gradually overgrow
the original differentiated tumor.
In a retrospective histopathological reviewon 297 primary enucleat-
ed eyes, the inverse relation between photoreceptor-related differenti-
ation and age at enucleation was also described (Eagle, 2009). In this
review examples of eosinophilic areas of photoreceptor differentiationand basophilic undifferentiated cells within the same tumor are
shown. Apparently, differentiated and undifferentiated cells can co-
existwithin the same tumor. Furthermore, SCNAamplitudes of chromo-
somes/chromosomal armswere always below1 copy (data not shown),
indicative of intra-tumoral heterogeneity. We therefore could envisage
that the mean expression of the photoreceptor gene signature in a
given tumor was determined by the ratio of differentiated cells and un-
differentiated cells. High expression of genes involved in mitosis ob-
served in undifferentiated tumors is in agreement with previous
observations of many mitotically active cells in undifferentiated tumor
areas (Eagle, 2009). This suggests that higher expression of the M-
phase andmRNA/ribosome synthesis signature could have been a result
of lower proportions of more differentiated and higher proportions of
less differentiated cells.
It has been suggested that differentiated areas in retinoblastomas are
benign precursor lesions of the undifferentiated areas (Dimaras et al.,
2008). This was based on the observation that differentiated eosinophil-
ic areas only had bi-allelic inactivation of RB1, while adjacent basophilic
undifferentiated areas had additional genetic lesions that probably
caused tumor progression. A progression model where benign differen-
tiated precursor cells can progress and expand to malignant retinoblas-
toma cells might explain the strong correlation of photoreceptorness
with tumor volumes. It is uncertain why larger and less differentiated
tumors with more SCNA were diagnosed at later age. Possibly, in case
RB1 inactivation occurred later in life, the affected cone precursors
were in a more mature, less proliferative state. Therefore, neoplastic le-
sions that arose from semi-matured cone precursors might be less pro-
liferative than those arising from more immature cone precursors.
When additional genetic lesions (e.g. SCNA) occur after late RB1 inacti-
vation, the resulting highly proliferative cells may quickly overgrow
the still small precursor lesion ultimately leading to tumors with rela-
tively few differentiated cells and many undifferentiated cells.
In addition, it could be that there was a diagnosis delay for tumors
that were initiated later due to tumor localization at the periphery
(Abramson and Gombos, 1996; Brinkert et al., 1998). Possibly, both ex-
planations are true and in combination explain the observed gene ex-
pression patterns and their relation with clinical and histopathological
variables.
In concordance with a progression model where genetic alterations
accumulate after loss of RB1 and cause malignant transformation, in-
creased frequencies of common SCNA at 1q, 2p (in particular the mini-
mal region of gain at 2p24.3 harboring MYCN), 6p, and 16q were
associated with loss of photoreceptorness (Fig. 5).
RNA signatures have been determined in several distinct retinoblas-
toma cohorts (Chakraborty et al., 2007; Ganguly and Shields, 2010;
McEvoy et al., 2011; Kapatai et al., 2013). Our results are in agreement
with a recent smaller-scale study (Kapatai et al., 2013), although our in-
terpretation of the identiﬁed differential expression signatures differs.
Kapatai et al., similar to the ﬁrst steps in our study, used unsupervised
hierarchical clustering on genome-wide expression estimates to stratify
23 retinoblastoma samples. Similar to our Ward's retinoblastoma clus-
ters 1, 2 and 3, Kapatai et al. found three retinoblastoma groups includ-
ing a small (n = 2) retina-like group that had been discarded from
further analyses. Explanation for the identiﬁed differences in expression
wasmainly focused on the cell of origin. Kapatai's group 1 tumors were
suggested to originate from retinal progenitor cells (RPCs) and group 2
tumors froma conephotoreceptor lineage. However, in a recent paper it
was shown that when RB1 was inactivated in retinal cell populations,
cone precursor numbers increased, while in RPCs TP53-responsive
genes were triggered causing a signiﬁcant decrease in RPC population
(Xu et al., 2014). This suggests that only cone photoreceptor precursors
become proliferative subsequent to RB1 loss and are likely the only cells
that can transform into retinoblastoma. Furthermore, the authors sug-
gested that RB1-deﬁcient cone precursors form differentiated retino-
blastomas that subsequently dedifferentiate and acquire non-cone
characteristics, in line with our observations. The study by Kapatai
Fig. 6. Photoreceptorness in relation to drug sensitivities. Relation between photoreceptorness and drug sensitivity determined by ex vivoMTT-assays. For each of twelve tested drugs, the
photoreceptorness is given on the x-axis and log10-transformed LC50 values on the y-axis. Drugs are sorted by the signiﬁcance of slope tests for regression between photoreceptorness and
LC50-values.
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group 1 tumors are advanced stages of group 2 tumors nor did they test
the continuity of the differential signatures.
In contrast, McEvoy et al. claimed that all retinoblastomas displayed
similar proﬁles, with co-expression of multiple normally incompatible
developmental pathways, also suggesting a retinal progenitor cell of or-
igin (McEvoy et al., 2011). The authors concluded that their retinoblas-
toma cohort was homogeneous, based on a principle component
analysis where they observed that themajority of retinoblastomas clus-
tered around a central core. However, a detailed inspection of the raw
data (Gene expression omnibus series GSE29686) revealed that also in
their cohort, unsupervised clustering identiﬁed retinoblastoma clusters
with gene expression differences similar to Kapatai's and our study. In
addition to the three clusters found by Kapatai et al. and our study, a
fourth cluster consisting of 8 samples was identiﬁed with high expres-
sion of lymphocyte markers, suggesting tumor inﬁltration with normal
lymphocytes. Expression of genes related to the immune system was
also found in our dataset (Table 2, gene cluster 2), although in lower
quantities and amplitude than in the McEvoy dataset. This gene signa-
ture could possibly relate to the microenvironment that might play an
important role in tumorigenesis. However, we have previously detected
similar lymphocyte inﬁltration in breast cancer expression proﬁles
(Massink et al., 2015). When samples with unclear origin (“normal ret-
ina” and “lymphocyte”) were discarded, differential gene signatures
were identiﬁed very comparable with our study. Similar to our study,
tumors with high expression of a photoreceptor signature showed low
expression of genes involved in M-phase, mRNA and ribosome synthe-
sis, also signifying a progression model. In conclusion, similar differen-
tial signatures could be detected in three distinct cohorts with
comparable relations to clinical characteristics.
The RNA signatures were also related to data from ex vivo drug sen-
sitivity assays for twelve different drugs, obtained from ex vivo drug as-
says of fresh retinoblastoma specimens of our cohort. Melphalan had
not been included, because when the experiments were performed,
the emphasis in the clinic was on other drugs. However we did include
other alkylating agents, such as carboplatin, cisplatin, ifosfamide and
thiotepa. For 10/12 (83.3%) chemotherapeutics, tumors with low
photoreceptorness were more sensitive (although the association was
not statistically signiﬁcant for each individual drug) than tumors withhigh photoreceptorness (p-value = 0.02). This suggests that in general
undifferentiated retinoblastoma is more chemosensitive compared
with differentiated retinoblastoma, at least ex vivo. Assuming that low
photoreceptorness is a surrogate marker for a high proportion of undif-
ferentiated mitotically active and highly proliferative cells, this hypoth-
esis seems plausible since chemotherapeutics act on proliferating cells.
Furthermore, it has long been recognized that photoreceptor differenti-
ation is more common in eyes enucleated after radiotherapy or chemo-
therapy because the well-differentiated part of the tumor is relatively
radio- or chemoresistant (Ts'o et al., 1970). More recently, it was ob-
served that retinoblastomas containing cavitary spaces, indicative of
well-differentiated retinoma areas, did not show a substantial decrease
in size after chemotherapy (Mashayekhi et al., 2005).
The association between photoreceptorness and drug sensitivity is
particularly clear in the case of actinomycin D, a drug that binds to
DNA and inhibits transcription by interfering with RNA elongation
(Sobell, 1985). The actinomycin D sensitivity of tumors with low
photoreceptorness, and thus high expression of M-phase and mRNA/ri-
bosome synthesis genes, could possibly be explained by the particular
sensitivity of ribosomal RNA synthesis to actinomycin D treatment.
Yet, the drug sensitivity data have to be interpreted with great cau-
tion, since it remains to be determined towhich extent the ex vivoMTT-
assays can predict therapy response. Furthermore, a signiﬁcant associa-
tion between photoreceptorness and drug sensitivity only means that
there is statistical evidence for a variance in drug response. This does
not necessarily mean that this drug is the best alternative for those pa-
tients. In case a drug would be effective for all retinoblastoma patients,
no signiﬁcant relation between drug sensitivity and photoreceptorness
would be detected.
Based on our comprehensive study of a relatively large cohort of reti-
noblastoma cases, we provide evidence for a tumor progressionmodel in
which early well-differentiated lesions advance to undifferentiated le-
sions with higher proliferative capacity. In this model, variability in gene
expression of RB1−/− retinoblastomas can be best explained by variability
in photoreceptor differentiation and tumor progression. Tumor progres-
sion could be driven by SCNA, since tumors with low photoreceptorness
and poor differentiation grades showed high frequencies of SCNA.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.ebiom.2015.06.022.
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